IONS insider buying and SEC filings, explained
Ionis Pharmaceuticals Inc. · CIK 874015
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- CA
- Fiscal year end
- Dec 31
- Former names
- ISIS PHARMACEUTICALS INC
Insider activity in the last 12 months
Bought
$1.1M
Insiders who bought
1
Sold (not marked 10b5-1)
$19.1M
Planned sales (10b5-1)
$108.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 16, 2026 | Sale | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 1,357 shares at about $43.54 ($59K). Holdings down 7% to 17,811 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 19, 2026, 9:40 PM ET |
| Oct 16, 2026 | Sale | Eric Swayze (EVP Research) sold 53 shares indirectly (by child) at $43.54 ($2K). Holdings by child down 12% to 390 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 19, 2026, 9:40 PM ET |
| Jul 30–31, 2026 | Purchase (code P) | Michael R Hayden (Director) bought 20,000 shares indirectly (by spouse) between Jul 30 and Jul 31 at about $52.94 ($1.1M), reported as a purchase (code P). Holdings by spouse up 500% to 24,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 31, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | C. Frank Bennett (EVP, Chief Scientific Officer) sold 20,536 shares directly and indirectly (by trust) at about $84.95 ($1.7M), marked as a 10b5-1 plan trade. Direct holdings down 7% to 75,018 shares. | SEC filing Filed Jul 9, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Allene M. Diaz (Director) sold 10,111 shares at about $85.42 ($864K), marked as a 10b5-1 plan trade. Holdings down 73% to 3,811 shares. | SEC filing Filed Jul 9, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Holly B. Kordasiewicz (EVP, Chief Development Officer) sold 362 shares at $84.30 ($31K), marked as a 10b5-1 plan trade. Holdings down 2% to 22,096 shares. | SEC filing Filed Jul 9, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Joseph Klein III (Director) sold 11,518 shares at about $79.04 ($910K), marked as a 10b5-1 plan trade. Holdings down 51% to 11,014 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Joseph Baroldi (EVP, Chief Business Officer) sold 5,635 shares indirectly (by spouse) at about $80.16 ($452K), marked as a 10b5-1 plan trade. Holdings by spouse down 55% to 4,669 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Patrick R. O'Neil (EVP CLO & General Counsel) sold 3,069 shares at $80.00 ($246K), marked as a 10b5-1 plan trade. Holdings down 5% to 61,470 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Eugene Schneider (EVP, Chf Clinical Develop Ofcr) sold 26,000 shares at about $81.05 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 25% to 77,114 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Eric Swayze (EVP Research) sold 10,602 shares at about $79.18 ($839K), marked as a 10b5-1 plan trade. Holdings down 33% to 21,759 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 24–26, 2026 | Planned (10b5-1) | Brett P Monia (CEO and Director) sold 85,637 shares between Jun 24 and Jun 26 at about $79.70 ($6.8M), marked as a 10b5-1 plan trade. Holdings down 26% to 245,571 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Spencer R. Berthelsen (Director) sold 8,000 shares at $73.49 ($588K), marked as a 10b5-1 plan trade. Holdings down 5% to 156,013 shares. | SEC filing Filed Jun 16, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Holly B. Kordasiewicz (EVP, Chief Development Officer) sold 60,846 shares at about $73.40 ($4.5M), marked as a 10b5-1 plan trade. Holdings down 73% to 22,458 shares. | SEC filing Filed Jun 16, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Spencer R. Berthelsen (Director) sold 8,000 shares at $75.67 ($605K), marked as a 10b5-1 plan trade. Holdings down 5% to 156,013 shares. | SEC filing Filed Jun 3, 2026 |
| May 13–14, 2026 | Planned (10b5-1) | Brett P Monia (CEO and Director) sold 4,536 shares between May 13 and May 14 at about $78.49 ($356K), marked as a 10b5-1 plan trade. Holdings down 2% to 242,662 shares. | SEC filing Filed May 15, 2026 |
| May 4, 2026 | Planned (10b5-1) | Joseph Loscalzo (Director) sold 77,289 shares at about $75.06 ($5.8M), marked as a 10b5-1 plan trade. Holdings down 68% to 36,330 shares. | SEC filing Filed May 6, 2026 |
| May 1, 2026 | Planned (10b5-1) | Joseph Klein III (Director) sold 10,111 shares at about $73.51 ($743K), marked as a 10b5-1 plan trade. Holdings down 48% to 11,014 shares. | SEC filing Filed May 5, 2026 |
| Apr 28, 2026 | Planned (10b5-1) | Joseph Baroldi (EVP, Chief Business Officer) sold 1,626 shares at about $71.79 ($117K), marked as a 10b5-1 plan trade. Holdings down 3% to 44,909 shares. | SEC filing Filed Apr 30, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | B. Lynne Parshall (Director) sold 5,000 shares at about $76.27 ($381K), marked as a 10b5-1 plan trade. Holdings down 9% to 51,344 shares. | SEC filing Filed Apr 17, 2026 |
| Apr 16, 2026 | Sale | Kyle Jenne (EVP, Chf GL Pdt Str Ofcr) sold 4,902 shares at about $75.17 ($368K). Holdings down 17% to 23,713 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 16, 2026 | Sale | Brian Birchler (EVP, Corp and Development Ops) sold 973 shares at about $75.04 ($73K). Holdings down 1% to 67,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 16, 2026 | Sale | Joseph Baroldi (EVP, Chief Business Officer) sold 5,619 shares at about $74.56 ($419K). Holdings down 11% to 46,535 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 6,193 shares at about $74.05 ($459K), marked as a 10b5-1 plan trade. Holdings down 27% to 16,348 shares. | SEC filing Filed Apr 2, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Joseph Klein III (Director) sold 22,321 shares at about $75.54 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 67% to 11,014 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 19, 2026 | Planned (10b5-1) | Eugene Schneider (EVP, Chf Clinical Develop Ofcr) sold 5,812 shares at about $70.97 ($412K), marked as a 10b5-1 plan trade. Holdings down 8% to 63,890 shares. | SEC filing Filed Mar 23, 2026 |
| Mar 16–17, 2026 | Planned (10b5-1) | Elizabeth L. Hougen (CFO) sold 225,220 shares between Mar 16 and Mar 17 at about $72.43 ($16.3M), marked as a 10b5-1 plan trade. Holdings down 73% to 82,660 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | Kyle Jenne (EVP, Chf GL Pdt Str Ofcr) sold 37,277 shares at about $75.85 ($2.8M), marked as a 10b5-1 plan trade. Holdings down 76% to 11,714 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 9, 2026 | Planned (10b5-1) | Patrick R. O'Neil (EVP CLO & General Counsel) sold 10,148 shares at about $75.25 ($764K), marked as a 10b5-1 plan trade. Holdings down 14% to 62,211 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 9–10, 2026 | Planned (10b5-1) | Brett P Monia (CEO and Director) sold 160,773 shares between Mar 9 and Mar 10 at about $75.35 ($12.1M), marked as a 10b5-1 plan trade. Holdings down 40% to 242,662 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 3–4, 2026 | Planned (10b5-1) | Joseph Loscalzo (Director) sold 1,032 shares between Mar 3 and Mar 4 at about $80.27 ($83K), marked as a 10b5-1 plan trade. Holdings down 3% to 36,330 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Joseph Klein III (Director) sold 21,332 shares at about $79.51 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 66% to 11,014 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Allene M. Diaz (Director) sold 54,878 shares at about $79.35 ($4.4M), marked as a 10b5-1 plan trade. Holdings down 94% to 3,811 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 20,106 shares at about $79.40 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 47% to 22,541 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | C. Frank Bennett (EVP, Chief Scientific Officer) sold 85,089 shares at about $79.23 ($6.7M), marked as a 10b5-1 plan trade. Holdings down 51% to 80,554 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3–4, 2026 | Planned (10b5-1) | Joseph Baroldi (EVP, Chief Business Officer) sold 6,659 shares directly and indirectly (by spouse) between Mar 3 and Mar 4 at about $79.74 ($531K), marked as a 10b5-1 plan trade. Direct holdings down 9% to 41,317 shares. | SEC filing Filed Mar 5, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Eric Swayze (EVP Research) sold 15,642 shares at about $81.76 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 33% to 32,105 shares. | SEC filing Filed Feb 13, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | B. Lynne Parshall (Director) sold 5,000 shares at about $82.72 ($414K), marked as a 10b5-1 plan trade. Holdings down 8% to 56,344 shares. | SEC filing Filed Feb 13, 2026 |
| Feb 6, 2026 | Planned (10b5-1) | Brett P Monia (CEO and Director) sold 29,430 shares at about $85.79 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 10% to 254,497 shares. | SEC filing Filed Feb 10, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | C. Frank Bennett (EVP, Chief Scientific Officer) sold 85,089 shares at about $82.93 ($7.1M), marked as a 10b5-1 plan trade. Holdings down 51% to 80,293 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 30, 2026 | Sale | Eric Swayze (EVP Research) sold 6,179 shares at about $82.93 ($512K). Holdings down 11% to 47,747 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | Eugene Schneider (EVP, Chf Clinical Develop Ofcr) sold 6,179 shares at about $83.45 ($516K). Holdings down 8% to 69,702 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | Patrick R. O'Neil (EVP CLO & General Counsel) sold 6,179 shares at about $83.53 ($516K). Holdings down 8% to 71,983 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | Brett P Monia (CEO and Director) sold 62,970 shares at about $82.72 ($5.2M). Holdings down 18% to 283,927 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | Elizabeth L. Hougen (CFO) sold 6,988 shares at about $83.24 ($582K). Holdings down 5% to 132,881 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | Brian Birchler (EVP, Corp and Development Ops) sold 6,179 shares at about $83.03 ($513K). Holdings down 9% to 66,247 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | C. Frank Bennett (EVP, Chief Scientific Officer) sold 5,885 shares at about $82.95 ($488K). Holdings down 6% to 100,293 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Sale | Joseph Baroldi (EVP, Chief Business Officer) sold 5,296 shares at about $82.96 ($439K). Holdings down 10% to 45,413 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 3,977 shares at about $81.34 ($323K), marked as a 10b5-1 plan trade. Holdings down 15% to 22,541 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 16, 2026 | Sale | Eric Swayze (EVP Research) sold 9,933 shares directly and indirectly (by child) at about $75.34 ($748K). Direct holdings down 19% to 41,935 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Eugene Schneider (EVP, Chf Clinical Develop Ofcr) sold 9,302 shares at about $75.59 ($703K). Holdings down 13% to 63,890 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Patrick R. O'Neil (EVP CLO & General Counsel) sold 9,191 shares at about $75.84 ($697K). Holdings down 12% to 66,171 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Brett P Monia (CEO and Director) sold 44,034 shares at about $74.82 ($3.3M). Holdings down 16% to 224,683 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Holly B. Kordasiewicz (EVP, Chief Development Officer) sold 4,141 shares at about $75.66 ($313K). Holdings down 22% to 14,718 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Kyle Jenne (EVP, Chf GL Pdt Str Ofcr) sold 1,823 shares at about $75.96 ($138K). Holdings down 10% to 16,389 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Elizabeth L. Hougen (CFO) sold 12,922 shares at about $75.22 ($972K). Holdings down 9% to 126,307 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 8,353 shares at about $75.95 ($634K). Holdings down 24% to 26,518 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Brian Birchler (EVP, Corp and Development Ops) sold 8,480 shares at about $75.11 ($637K). Holdings down 12% to 60,435 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | C. Frank Bennett (EVP, Chief Scientific Officer) sold 8,977 shares at about $75.15 ($675K). Holdings down 9% to 94,757 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 16, 2026 | Sale | Joseph Baroldi (EVP, Chief Business Officer) sold 8,056 shares directly and indirectly (by spouse) at about $75.75 ($610K). Direct holdings down 15% to 40,431 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 20, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 44,199 shares at about $85.08 ($3.8M), marked as a 10b5-1 plan trade. Holdings down 72% to 17,494 shares. | SEC filing Filed Jan 9, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Eric Swayze (EVP Research) sold 23,463 shares at about $79.12 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 44% to 30,453 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 1, 2025 | Planned (10b5-1) | Joseph H. Wender (Director) sold 28,000 shares indirectly (by trust) at about $80.82 ($2.3M), marked as a 10b5-1 plan trade. Holdings by trust down 44% to 36,035 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Joseph Klein III (Director) sold 12,000 shares indirectly (by trust) at $80.00 ($960K), marked as a 10b5-1 plan trade. Holdings by trust down 100% to 0 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Shannon L. Devers (EVP, Chief Human Resources Ofc) sold 16,777 shares at about $80.91 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 49% to 17,494 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 6, 2025 | Planned (10b5-1) | Brian Birchler (EVP, Corp and Development Ops) sold 8,000 shares at about $76.17 ($609K), marked as a 10b5-1 plan trade. Holdings down 14% to 48,826 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 5–6, 2025 | Planned (10b5-1) | Richard S Geary (EVP, Chief Development Officer) sold 34,639 shares between Nov 5, 2025 and Nov 6, 2025 at about $75.69 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 37% to 59,657 shares. | SEC filing Filed Nov 7, 2025 |
| Oct 31–Nov 3, 2025 | Planned (10b5-1) Amended filing | Richard S Geary (EVP, Chief Development Officer) sold 90,929 shares between Oct 31, 2025 and Nov 3, 2025 at about $75.11 ($6.8M), marked as a 10b5-1 plan trade. Holdings down 60% to 59,657 shares. This amends a filing from Nov 3, 2025. | SEC filing Filed Nov 7, 2025 |
88 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow IONS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.